22 Jul Kytopen
Michael Chiu, CEO
Oct. 12 | 10:00am | Rentschler ATMP Ballroom
Kytopen, a transformative biotechnology spin-out from MIT, specializes in scalable gene delivery platforms to expedite cell therapy development while reducing costs. The Flowfect® solution enables rapid, customizable, and efficient non-viral delivery of complex genome engineering materials, including CRISPR, mRNA, and DNA, to living medicines. Flowfect® is realized in high-throughput and large-volume configurations, facilitating consistent delivery across all stages of therapeutic development through predictive scaling. May 2023, Kytopen introduced the Flowfect Discover™ early-access program, strategically placing the device at industry-leading Contract Development and Manufacturing Organizations (CDMOs) and Translational Academic Medical Centers. Flowfect Discover™ empowers researchers to confidently screen and optimize delivery with up to 96 small-volume samples in minutes before translating seamlessly to large-scale manufacturing. By integrating Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device, developers can overcome manufacturing challenges during the discovery stage, foster faster and more cost-effective innovation, and bring cell therapy to production and benefit more patients.